Splenic hemangiosarcoma is an aggressive cancer of blood vessel cells that disproportionately affects large breed dogs, often presenting as a sudden life-threatening emergency with few prior warning signs.
Splenic hemangiosarcoma presents unique welfare challenges because of its sudden, catastrophic presentation. Dogs experiencing splenic rupture are in haemorrhagic shock — pale gums, rapid weak pulse, collapse — and require emergency stabilisation before any welfare decisions can be made. This leaves owners in crisis without time to make considered choices. Post-surgical recovery is typically good — splenectomy is well-tolerated — but the median survival of 4-6 months with chemotherapy means the treatment period is substantial relative to remaining life expectancy. Chemotherapy in dogs generally causes milder side effects than in humans, but some dogs experience nausea, fatigue and appetite loss. The high recurrence rate means owners must cope with anticipatory grief throughout treatment. Euthanasia timing is critical: delayed decision-making prolongs suffering in the final stages, when recurrence causes progressive breathlessness from pulmonary metastases. Quality of life assessment tools help owners and vets navigate end-of-life timing.